News
Queens University spin-out Re-Vana Therapeutics has agreed a $1bn deal with biopharma giant Boehringer Ingelheim.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback